Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CRYSVITA vs BLENREP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fibroblast growth factor 23 (FGF23) inhibitor; increases renal phosphate reabsorption and 1,25-dihydroxyvitamin D production by blocking FGF23 activity.
Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.
Treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 1 year and older,Treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized
FDA-approved for relapsed or refractory multiple myeloma in adults who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.
2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
16.4 days (terminal elimination half-life); supports monthly subcutaneous dosing.
The terminal elimination half-life of belantamab mafodotin is approximately 12 days (range 9-19 days). This supports a dosing interval of every 3 weeks, allowing for drug clearance between cycles while maintaining therapeutic exposure.
Metabolized into small peptides and amino acids via catabolic pathways; not metabolized by cytochrome P450 enzymes.
Belantamab mafodotin is likely metabolized via proteolytic degradation into small peptides and amino acids; MMAF is a substrate of CYP3A and P-glycoprotein, but the contribution of CYP3A to clearance is limited.
Renal (minimal, as intact antibody); catabolized into small peptides and amino acids; no biliary/fecal elimination of intact drug.
Blenrep (belantamab mafodotin) is eliminated primarily via catabolism, with no significant renal or biliary excretion of intact drug. The small molecule toxin, monomethyl auristatin F (MMAF), is excreted via feces (72%) and urine (28%) after release from the antibody conjugate.
Target-mediated binding to FGF23; low nonspecific binding to other plasma proteins (typical for m Abs).
Belantamab mafodotin is highly protein-bound (>99%) to plasma proteins, predominantly to albumin. The released MMAF is also extensively protein-bound (approximately 90% to albumin).
3.8 L (approximately 0.05 L/kg for a 70 kg adult); indicates limited extravascular distribution (confined mainly to plasma volume).
The volume of distribution of belantamab mafodotin is approximately 7.8 L (range 4.5-12.4 L), which is slightly greater than plasma volume, indicating limited extravascular distribution. The Vd is not typically normalized to body weight; however, dosing is weight-based (mg/kg) to account for interpatient variability.
Subcutaneous: ~78% relative to intravenous administration (absolute bioavailability not determined due to lack of IV formulation).
Blenrep is administered as an intravenous infusion; thus, bioavailability is 100% by the intravenous route. No oral or other routes are approved.
No dose adjustment required in renal impairment. Safety and efficacy not established in severe renal impairment (e GFR <30 m L/min/1.73 m²) or on dialysis.
For moderate renal impairment (e GFR 30-59 m L/min/1.73 m²): reduce dose to 1.9 mg/kg. For severe renal impairment (e GFR 15-29 m L/min/1.73 m²): not recommended. For e GFR <15 m L/min/1.73 m²: contraindicated.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 1.9 mg/kg. Child-Pugh Class C: not recommended.
1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.
Safety and efficacy not established; no specific pediatric dosing guidelines available.
No specific dose adjustment recommended for elderly patients (≥65 years). Use based on weight and clinical response.
No specific dose adjustment recommended based on age alone; monitor renal function and consider dose adjustment per renal impairment guidelines.
None.
WARNING: OCULAR TOXICITY. Blenrep (belantamab mafodotin) causes severe ocular toxicity, including keratopathy and changes in visual acuity, which may require dose modification or discontinuation. Perform ophthalmic exams prior to each dose. Use only in patients who have received at least 4 prior therapies.
Hypersensitivity reactions including anaphylaxis,Hyperphosphatemia and risk of nephrocalcinosis/nephrolithiasis,Dental abscesses and infections,Local injection site reactions
Ocular toxicity (keratopathy, visual acuity changes),Thrombocytopenia,Infusion-related reactions,Hepatotoxicity (increased transaminases),Embryo-fetal toxicity
Concomitant use with phosphate binders or active vitamin D analogs (calcitriol, paricalcitol, doxercalciferol),Severe renal impairment or end-stage renal disease
None known
Avoid high-phosphorus foods and beverages (e.g., dairy products, nuts, seeds, whole grains, cola, chocolate, organ meats) while on CRYSVITA, as they may increase serum phosphorus levels and risk of hyperphosphatemia. Dietary phosphate restriction is recommended. No specific food-drug interactions known; however, maintain consistent phosphorus intake between doses.
No specific food interactions known. Maintain adequate hydration.
CRYSVITA (burosumab) is a monoclonal antibody that inhibits fibroblast growth factor 23 (FGF23). There are no adequate and well-controlled studies in pregnant women. In animal studies, administration of burosumab to pregnant monkeys during organogenesis resulted in no teratogenic effects at doses up to 5.9 times the human dose. However, due to the mechanism of action, potential risks include disturbances in phosphate and vitamin D metabolism which may affect fetal skeletal development. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
FDA Pregnancy Category D. First trimester: belantamab mafodotin is an antibody-drug conjugate; the cytotoxic component may cause fetal harm. Second and third trimesters: risk of fetal toxicity and teratogenicity due to the microtubule inhibitor; avoid use unless maternal benefit outweighs risk.
It is not known whether burosumab is excreted in human milk. As a monoclonal antibody, burosumab is likely to be minimally transferred into breast milk and is expected to undergo proteolytic digestion in the gastrointestinal tract. The M/P ratio is unknown. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for CRYSVITA and any potential adverse effects on the breastfed child.
No data on presence in human milk. M/P ratio unknown. Advise to discontinue breastfeeding during treatment and for at least 3 months after last dose due to potential for severe adverse reactions in breastfed infants.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of burosumab may be altered due to pregnancy-induced physiological changes, including increased plasma volume and altered clearance. Monitor serum phosphorus levels and adjust dosing based on clinical response and tolerability. Consider dose adjustments if significant changes in serum phosphorus or adverse effects occur.
No specific dose adjustments in pregnancy established. Use is not recommended; if unavoidable, consider dose reduction based on tolerability (e.g., for ocular toxicity). No pharmacokinetic data available to guide adjustments.
CRYSVITA (burosumab) is a recombinant human monoclonal Ig G1 antibody to fibroblast growth factor 23 (FGF23), indicated for X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 1 year and older. Administer subcutaneously every 2 weeks (pediatric: starting 0.8 mg/kg, max 1.2 mg/kg; adult: 1.0 mg/kg, max 90 mg). Monitor serum phosphorus closely, aiming for age-appropriate normal range. Do not initiate if serum phosphorus is within normal range. Concomitant use with oral phosphate and active vitamin D analogs is not recommended. May cause injection site reactions, headache, and hyperphosphatemia. Discontinue if severe hypersensitivity occurs. Pregnancy and breastfeeding: limited data; use only if clearly needed.
Monitor for ocular toxicity, including keratitis and uveitis; perform ophthalmic exams at baseline and during therapy. Premedicate with corticosteroids and vasoconstrictors to reduce infusion reactions. Blenrep is a BCMA-directed antibody-drug conjugate for relapsed/refractory multiple myeloma. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min).
CRYSVITA is given as an injection under the skin every 2 weeks. Do not miss doses.,Do not take phosphate supplements or active vitamin D (e.g., calcitriol) while on CRYSVITA unless specifically instructed by your doctor.,Report symptoms of high phosphorus levels: muscle cramps, numbness, tingling, or irregular heartbeat.,Common side effects include injection site reactions (redness, pain, swelling), headache, and back pain.,Pregnancy and breastfeeding: inform your doctor if you are pregnant, plan to become pregnant, or are nursing.,Store CRYSVITA in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Allow to reach room temperature before injecting.
Inform your doctor immediately if you experience blurred vision, eye pain, or light sensitivity.,You will need eye exams before and during treatment.,Report any signs of infusion reactions such as chills, fever, or difficulty breathing.,Use effective contraception during treatment and for 4 months after the last dose.,Avoid driving or operating machinery if you have vision changes.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CRYSVITA vs BLENREP, answered by our medical review team.
CRYSVITA is a Monoclonal Antibody that works by Fibroblast growth factor 23 (FGF23) inhibitor; increases renal phosphate reabsorption and 1,25-dihydroxyvitamin D production by blocking FGF23 activity.. BLENREP is a Antineoplastic, Monoclonal Antibody that works by Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CRYSVITA and BLENREP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CRYSVITA is: 1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.. The standard adult dose of BLENREP is: 2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CRYSVITA and BLENREP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CRYSVITA is classified as Category C. CRYSVITA (burosumab) is a monoclonal antibody that inhibits fibroblast growth factor 23 (FGF23). There are no adequate and well-controlled studies in pregnant women. In animal stud. BLENREP is classified as Category C. FDA Pregnancy Category D. First trimester: belantamab mafodotin is an antibody-drug conjugate; the cytotoxic component may cause fetal harm. Second and third trimesters: risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.